Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Avery D, Posey"'
Autor:
James L Gulley, Deborah Collyar, Pedro J Romero, Christian M Capitini, Leisha A Emens, Avery D Posey, Patrick Hwu, Jennifer A Wargo, Ann W Silk, Ana Carrizosa Anderson, Tullia C Bruno
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Cancer immunotherapy has flourished over the last 10–15 years, transforming the practice of oncology and providing long-term clinical benefit to some patients. During this time, three distinct classes of immune checkpoint inhibitors, chimeric antig
Externí odkaz:
https://doaj.org/article/ba0feaa1364741509df21dfe108b7d2c
Autor:
Ian D. Ferguson, Bonell Patiño-Escobar, Sami T. Tuomivaara, Yu-Hsiu T. Lin, Matthew A. Nix, Kevin K. Leung, Corynn Kasap, Emilio Ramos, Wilson Nieves Vasquez, Alexis Talbot, Martina Hale, Akul Naik, Audrey Kishishita, Priya Choudhry, Antonia Lopez-Girona, Weili Miao, Sandy W. Wong, Jeffrey L. Wolf, Thomas G. Martin, Nina Shah, Scott Vandenberg, Sonam Prakash, Lenka Besse, Christoph Driessen, Avery D. Posey, R. Dyche Mullins, Justin Eyquem, James A. Wells, Arun P. Wiita
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
The myeloma cell surface proteome regulates plasma cell biology and delineates therapy targets. Here, the authors profile the myeloma surfaceome at baseline and in drug resistance, finding the potential target CCR10, and include a streamlined approac
Externí odkaz:
https://doaj.org/article/c60c92825695486592fb827ec64cf75c
Autor:
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O’Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
KRAS is commonly mutated at codon 12 in several cancer types, offering a unique opportunity for the development of neoantigen-targeted immunotherapy. Here the authors present a pipeline for the prediction, identification and validation of HLA class-I
Externí odkaz:
https://doaj.org/article/5c32458bd77b40989a4cd89c57021223
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 12, Iss , Pp 145-156 (2019)
T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, inves
Externí odkaz:
https://doaj.org/article/0040ed529c8846b3a3fe803c78f2835d
Autor:
Yibo Yin, Alina C. Boesteanu, Zev A. Binder, Chong Xu, Reiss A. Reid, Jesse L. Rodriguez, Danielle R. Cook, Radhika Thokala, Kristin Blouch, Bevin McGettigan-Croce, Logan Zhang, Christoph Konradt, Alexandria P. Cogdill, M. Kazim Panjwani, Shuguang Jiang, Denis Migliorini, Nadia Dahmane, Avery D. Posey, Jr., Carl H. June, Nicola J. Mason, Zhiguo Lin, Donald M. O’Rourke, Laura A. Johnson
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 20-38 (2018)
We generated two humanized interleukin-13 receptor α2 (IL-13Rα2) chimeric antigen receptors (CARs), Hu07BBz and Hu08BBz, that recognized human IL-13Rα2, but not IL-13Rα1. Hu08BBz also recognized canine IL-13Rα2. Both of these CAR T cell construc
Externí odkaz:
https://doaj.org/article/c4f59e6339ce4efa84b3ecf00abab181
Autor:
Shawna K. Brookens, Avery D. Posey
Publikováno v:
The Cancer Journal. 29:28-33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93cba98ddaceb792000ffd28479af274
https://doi.org/10.1097/ppo.0000000000000636
https://doi.org/10.1097/ppo.0000000000000636
Autor:
John T. Keane, Avery D. Posey
Publikováno v:
Cells, Vol 10, Iss 12, p 3356 (2021)
T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric anti
Externí odkaz:
https://doaj.org/article/1f55755916c04774aa085ce23e64e046
Autor:
Keisuke Watanabe, M. Angela Aznar, Shunichiro Kuramitsu, Mikko Siurala, Tong Da, Sangya Agarwal, Decheng Song, John Scholler, Antonia Rotolo, Avery D Posey, Alain H Rook, Paul L. Haun, Marco Ruella, Regina M. Young, Carl H June
Publikováno v:
Blood Advances.
A challenge when targeting T cell lymphoma with chimeric antigen receptor (CAR) T cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity on normal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3790c43bc93982d0d2905e9ec0074f91
https://doi.org/10.1182/bloodadvances.2022008327
https://doi.org/10.1182/bloodadvances.2022008327
Autor:
Sonia Guedan, Carl H. June, Ramon Alemany, Regina M. Young, Tong Da, Carolyn Shaw, Avery D. Posey, Carlos Alberto Fajardo, Anna Wing
S1. Therapeutic index of EGFR-targeting CART cells and the OAd-BiTE. S2. The Combination of FR-CART cells and OAd-BiTE mediates tumor regression in mice bearing pancreatic xenograft tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106ae55fa148a68429011d9364396e1d
https://doi.org/10.1158/2326-6066.22536343.v1
https://doi.org/10.1158/2326-6066.22536343.v1
Autor:
Sonia Guedan, Carl H. June, Ramon Alemany, Regina M. Young, Tong Da, Carolyn Shaw, Avery D. Posey, Carlos Alberto Fajardo, Anna Wing
The file contains the supplementary table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::392917d8059df4f780d7e4d536504654
https://doi.org/10.1158/2326-6066.22536340
https://doi.org/10.1158/2326-6066.22536340